Recommendations for the organization of care in paediatric radiation oncology across Europe : a SIOPE-ESTRO-PROS-CCI-Europe collaborative project in the framework of JARC by Janssens, Geert O. et al.
European Journal of Cancer 114 (2019) 47e54Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.ejcancer .comCurrent PerspectiveRecommendations for the organisation of care in
paediatric radiation oncology across Europe: a
SIOPEeESTROePROSeCCI-Europe collaborative
project in the framework of the JARC*Geert O. Janssens a,b,*, Beate Timmermann c, Anne Laprie d,e,
Henry Mandeville f, Laetitia Padovani g, Cyrus Chargari h, Neige Journy i,
Lejla Kameric j, Anita Kienesberger j, Melanie Brunhofer j,
Olga Kozhaeva k, Chiara Gasparotto l, Pamela Kearns k,l,m,
Tom Boterberg n, Yolande Lievens l,m,n, Gilles Vassal k,oa Department of Radiation Oncology, University Medical Centre Utrecht, the Netherlands
b Princess Maxima Centre for Paediatric Oncology, Utrecht, the Netherlands
c Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West
German Cancer Centre (WTZ), German Cancer Consortium (DKTK), Germany
d Department of Radiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole,
Toulouse, France
e Toulouse NeuroImaging Center, ToNIC, INSERM Universite´ Toulouse III Paul Sabatier, Toulouse, France
f Department of Radiotherapy, The Royal Marsden Hospital, Sutton, United Kingdom
g Department of Radiation Oncology, CRCM, UMR 1068 Inserm 7258 CNRS, Assistance Publique Hoˆpitaux de Marseille,
Marseille, France
h Department of Radiation Oncology, Gustave Roussy, Villejuif, France
i INSERM Unit 1018, Centre for Research in Epidemiology and Population Health (CESP), Cancer and Radiations Group,
Gustave Roussy, Villejuif, France
j Childhood Cancer International - Europe, Vienna, Austria
k European Society for Paediatric Oncology (SIOP Europe), Brussels, Belgium
l European Society for Radiotherapy & Oncology (ESTRO), Brussels, Belgium
m Institute of Cancer and Genomic Sciences, NIHR Birmingham Biomedical Research Centre, University of Birmingham,
Birmingham, United Kingdom
n Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
o Department of Clinical Research, Gustave Roussy, Paris-Sud University, Paris, FranceReceived 19 February 2019; accepted 4 March 2019
Available online 3 May 2019* SIOPE-affiliated countries (https://www.siope.eu/about-siope/members/), plus Albania, Estonia and Montenegro.
* Corresponding author: Dept. of Radiation Oncology, University Medical Center Utrecht and Princess Maxima Centre for Pediatric Oncology,
Utrecht, the Netherlands.
E-mail address: g.o.r.janssens@umcutrecht.nl (G.O. Janssens).
https://doi.org/10.1016/j.ejca.2019.03.003
0959-8049/ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
G.O. Janssens et al. / European Journal of Cancer 114 (2019) 47e5448KEYWORDS
Paediatric;
Radiotherapy;
Standards of care;
Recommendations;
Radiation oncology;
Paediatric oncology;
Childhood cancer;
SIOPETable 1
Childhood cancer incidence and morta
tries: 2018 (source: Globocan).
Type of cancer
(age: 0e19 years)
I
Haematologic malignancies 9
Brain tumours 3
Solid tumours 7
Total 2
SIOPE, European Society for PaediatriAbstract Disparities in survival and long-term side-effects from paediatric cancer are
observed across European Society for Paediatric Oncology (SIOPE)eaffiliated countries.
The Joint Action on Rare Cancers (JARC) is a project supported by the European Union
and member states aiming to formulate recommendations on rare cancers, including paediatric
malignancies, to reduce inequalities and to improve health outcomes. Most paediatric cancers
are treated by a combination of systemic agents, surgery and/or radiotherapy. Radiotherapy
for children is becoming increasingly complex because of the growing availability of new mo-
dalities and techniques and the evolution in molecular biology. These added challenges have
the potential to enhance disparities in survival and side-effects between countries, but also
among centres in the same country. To tackle radiotherapy-related inequalities, representa-
tives of SIOPE, European SocieTy for Radiotherapy and Oncology, Paediatric Radiation
Oncology Society and Childhood Cancer InternationaleEurope defined ‘standard’ and
‘optional’ levels to deliver Good Clinical Practiceecompliant treatment in paediatric radiation
oncology with a focus on patient-related care, education and training. In addition, more than
250 paediatric radiotherapy centres across the SIOPE-affiliated countries have been mapped.
For a better understanding of resources in paediatric radiotherapy, JARC representatives are
working on an online survey for paediatric radiation oncologists of each centre in SIOPE-affil-
iated countries. The outcome of this survey will give an insight into the strengths and weak-
nesses of paediatric radiotherapy across SIOPE-affiliated countries and can be relevant for
European Reference Networks in terms of collaboration pathways and referrals in paediatric
radiotherapy.
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Close collaboration among professionals in paediatric
haematology and oncology has resulted in a significant
survival benefit over the last decades [1]. Despite these
efforts, disparities in survival rates of more than 20%
and long-term side-effects are a reality across Europe
[2e6]. To reduce these inequalities and to improve
health outcomes in European countries, a project enti-
tled ‘European Standards of Care for Children with
Cancer’ had been initiated with the support of the Eu-
ropean Union (EU) [7,8]. This project consolidated the
ideal requirements for centres specialised in the treat-
ment of children with cancer across Europe.
Annually, in countries affiliated to SIOP Europe,
almost 25,000 new patients aged 0e19 years are diag-
nosed with cancer of whom more than 4000 will die
because of disease progression or disease-related toxicity
(Table 1) [9]. Most paediatric cancers are treated by a
combination of systemic agents, surgery and/orlity in SIOPE-affiliated coun-
ncidence Mortality
938 1643
184 1168
467 1503
4,240 4314
c Oncology.radiotherapy (RT), making paediatric radiation oncol-
ogists core medical members of the childhood cancer
treatment team. Historically, RT for children was
delivered using a standard-treatment-for-all approach.
Nowadays, with the growing availability of new mo-
dalities and techniques, RT for children is becoming
particularly complex and requires an individual
approach. In addition, there has been a marked increase
in the understanding of the molecular biology of pae-
diatric cancers, and in addition, the potential late effects
of RT on normal organ structure and function are being
recognised and quantified in relation to the treatment
given.
The Joint Action on Rare Cancers (JARC) is a
multistakeholder collaborative project supported by
the EU and member states, which aims to formulate
policy recommendations on rare cancers, including
paediatric malignancies [10]. For RT-related issues in
paediatric malignancies (Work Package 9 [WP9]), there
is involvement from strategic partners including SIOPE
(and its QUARTET1 project), Childhood Cancer
InternationaleEurope (CCI-Europe), European Soci-
eTy for Radiotherapy and Oncology (ESTRO) and
Paediatric Radiation Oncology Society (PROS). To
achieve the best possible outcomes for children, treat-
ment centres should meet an appropriate level of stan-
dards and have access to continuously updated ‘best
practice’ information. A recent survey in the context of1 Quality and Excellence in Radiotherapy and Imaging for Children
and Adolescents with Cancer across Europe in Clinical Trials.
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paediatric radiation oncology are available in only three
(France, Germany and United Kingdom [UK]) of 30
European countries responding to the survey.
Representatives of the strategic partners defined
‘standard’ and ‘optional’ levels to deliver Good Clinical
Practice (GCP)ecompliant treatment in paediatric ra-
diation oncology. Given the complexity of paediatric
radiation oncology, the list of items will focus on patient
care, education and training, as well as the organisation
of patient-related research.
2. European Standards of care for paediatric radiation
oncology
2.1. Patient care
2.1.1. Tumour board
2.1.1.1. Standard. Patients with newly diagnosed tu-
mours, treatment response evaluations or any suspi-
cion of progression should be discussed in a
multidisciplinary team meeting, which registers treat-
ment decisions including the indication for RT, timing
of treatment and requirement for concomitant treat-
ment modalities. Team meetings should be scheduled
on a weekly basis and consist of all core medical spe-
cialists, including at least one paediatric oncologist,
radiation oncologist and (neuro)surgeon, with addi-
tional support from a radiologist, a nuclear medicine
physician and a pathologist. To allow specialists
working at distance from the board room, a remote
conferencing system ideally should be available
(Table 2eA).
2.1.1.2. Optional. To enhance the quality of the discus-
sion for specific patient groups, other specialists such as
surgeons, neurologists, ophthalmologists, endocrinolo-
gists and/or clinical geneticists may join.
2.1.2. Radiotherapy consultation
2.1.2.1. Standard. Within an informational talk with the
family and the patient, the paediatric radiation oncolo-
gist discusses the indication for radiation therapy in the
context of the disease and/or other treatment modalities.
He or she explains the procedure related to RT (fixation,
imaging, anaesthesia and treatment), the potential acute
and late side-effects and the logistics related to the RT
process. When a significant RT dose to the ovaries or
testes is expected, referral for fertility preservation
should be considered and discussed with the family.
Typically, both parents (or legal guardians) are
involved. It is recommended to fully inform children
from the age of 12e14 years or depending on the indi-
vidual stage of development. To explain RT to children,
informal booklets, textbooks, apps or movies are
available, adapted for different age groups. Guided
tours of the department can be reassuring for children,helping to familiarise them with the new surroundings.
Outside working hours, a 24-h on-call service is essential
to manage emergencies or complications, if necessary,
via colleague paediatric oncologists. To cover holiday
periods or weekends, at least two radiation oncologists
with knowledge of paediatric tumours are available
(Table 2eB).2.1.2.2. Optional. Play specialists (or equivalent
personnel) prepare and support the child before and
during RT, using a variety of techniques which can
include mini-computed tomography (CT), magnetic
resonance imaging (MRI) and/or linear accelerator
(LINAC). Play specialists have been shown to signifi-
cantly reduce the requirement for anaesthesia in young
children [11]. Ideally, age-adapted environments should
be available, which may include a playground for
children.2.1.3. Radiotherapy treatment preparation
2.1.3.1. Standard. To obtain optimal daily reproduc-
ibility during RT, the department is able to use fixation
tools (thermoplastic mask, neck support, vacuum
mattress and body cast), individually manufactured by
experienced radiation therapists (RTTs) or mould room
technicians. Three-dimensional CT-based treatment
planning is required for optimal geometrical and
anatomical information. In the era of advanced diag-
nostic imaging, software and knowledge on clinical
image processing, in particular for coregistration, a
central review of treatment plans (e.g. QUARTET) is
needed. Before RT treatment planning starts, the RTT
or dosimetrist is instructed about the positioning of the
child, the concerned body region and specific dose
constraints to maximise target dose coverage and to
reduce the risk of late effects. When a clinically signifi-
cant benefit is expected with advanced photon tech-
niques, proton beam therapy or brachytherapy, the
patient should be referred to a specialised centre defined
as the relevant partnering reference institution if not
available in-house. To maximise the chances of
compliance from the child, longer time slots are
needed for preparation. In cases where there is a lack
of compliance of a child, especially for those aged 3
years or younger, the department can prepare treatment
with the patient being under anaesthesia (Table 2eC).2.1.3.2. Optional. State-of-the-art RT departments
implement 4D information when motion of the target
volume is expected and rely on MRI or positron-emis-
sion tomography (PET)eCT images to prepare the RT
process. Besides conventional highly conformal RT,
intensity-modulated RT and proton beam therapy are
being used in an increasing number of paediatric
patients and are accessible via defined cooperation
Table 2
Patient care.
Workflow and goals Personnel Equipment
A. Tumour board Standard or mandatory Standard or mandatory
Diagnosis þ staging primary
tumour, recurrence
Multidisciplinary team Board room
Treatment protocol Paediatric oncologist, (neuro)surgeon,
radiation oncologist
Remote conferencing system available
Response on treatment Supported by
Registration Radiologist, (nuclear medicine physician),
pathologist
(Bi)weekly
Optional Optional
Neurologist
Ophthalmologist
Endocrinologist
Clinical geneticists
B. RT Consultation Standard or mandatory Standard or mandatory
Discussion on RT procedure
(fixation, imaging,
anaesthesia)
At least 2 radiation oncologists with
knowledge on paediatric tumours
Child-friendly environment
Discussion on potential acute
late side-effects
24-h on-call service, if necessary via
cooperation
Informational booklet, textbook, app or movie
Discussion on logistics related
to RT
Reference network for fertility
preservation
Guided tour in the department
Optional Optional
Play specialist or equivalent Healing environment
Play area for children
Mini-CT/MRI/LINACS
C. Treatment preparation Standard or mandatory Standard or mandatory
Fixation (mask, neck support,
body cast, vacuum
mattress)
Dedicated RTTs (mould room, CT and
PET, MRI if applicable)
Mould room with dedicated tools for fixation
Image acquisition RTT with knowledge of clinical image
processing (coregistration)
CT
Image coregistration RTT with interest in paediatric oncology Access to MRI, when indicated
RT planning Radiation oncologist with knowledge on
paediatric tumours
Software for image fusion (MRePETeCT)
RT QA (intern) Clinical physicist 3D delineation system
RT QA (extern) (Paediatric) anaesthesiologist 3D treatment planning system for photonseelectrons
Anaesthesia equipment
Reference network for brachytherapy
Reference network for advanced photon therapy
Reference network for proton therapy
Access to QUARTET or central review of RT plans
(study patients)
Child-friendly environment
Optional Optional
(4D) CT
(4D) PET-CT
(4D) MRI
(Rotational) IMRTeIMPT
Stereotactic RT
3D treatment planning system for protons
Reanimation unit for paediatrics
Brachytherapy operation equipment
D. RT treatment delivery Standard or mandatory Standard or mandatory
Delivery of conformal
radiotherapy
RTT with affinity for children Photoneelectron therapy
To respect onset of RT
following international
guidelines
Radiation oncologist, weekly or biweekly
patient contact
Patient position verification tools with correction
protocols
To respect overall treatment
time
Paediatric oncologist available Easy access to paediatric oncology unit (e.g. concomitant
treatment)
Anaesthesiologist Anaesthesia equipment
Adapted time slots to treat children
Child-friendly environment
G.O. Janssens et al. / European Journal of Cancer 114 (2019) 47e5450
Table 2 (continued )
Workflow and goals Personnel Equipment
Optional Optional
Daily online position correction protocols
Cone beam CT scan
Image-guided RT
Adaptive RT
Stereotactic RT
Proton therapy
MRI-guided RT
Brachytherapy
E. Follow-up after RT Standard or mandatory Standard or mandatory
Awareness of late side-effects of
treatment
Radiation oncologist Child-friendly environment
Registration of late toxicity
Optional Optional
Paediatric nurse LATER multidisciplinary outpatient clinic
CT, computed tomography; PET, positron-emission tomography; RT, radiotherapy; RTT, radiation therapist; MRI, magnetic resonance imaging;
LINAC, linear accelerator; QA, quality assurance; IMRT, intensity modulated radiation therapy; IMPT, intensity modulated proton therapy;
LATER, late effects after childhood cancer.
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ablative RT or brachytherapy remain limited.
2.1.4. Radiotherapy treatment delivery
2.1.4.1. Standard. With the exception of a limited num-
ber of indications (e.g. flank RT), opposing photon
beams are avoided, and highly conformal RT should be
the standard of care. Regardless of any study partici-
pation, it is recommended to respect the defined timing
for the start of RT and overall treatment duration, as
mentioned in the treatment protocols. In the RT treat-
ment room, at least one RTT or healthcare provider has
particular affinity with paediatric patients. Patient po-
sition verification protocols using laser, light field and
X-ray systems are essential to assure target coverage and
to reduce the RT dose to normal structures. Time slots
are adapted to the compliance of the child. In case of
lack of compliance, the department can deliver RT with
the patient being under general anaesthesia within the
time restrictions of the tumour protocol (Table 2eD).
2.1.4.2. Optional. Daily positioning verification by X-
ray, cone beam CT or MRI scans with online correc-
tions can facilitate a reduction in margins around the
clinical target volume and consequently limit normal
tissue exposure to RT.
2.1.5. Radiotherapy follow-up
2.1.5.1. Standard. Awareness of late side-effects caused
by RT after a childhood cancer treatment is important.
Routine follow-up visits and systematic registration of
moderate to severe long-term side-effects are key for
management of late toxicities, improving understanding
and directing strategies of prevention for childhood
cancer survivors and future generations (Table 2eE).
2.1.5.2. Optional. Participation by the radiation oncolo-
gist in a multidisciplinary outpatient clinic is preferred,
given the complexity of side-effects due to the differenttreatment modalities observed in a significant number of
long-term survivors.
2.2. Education and training
2.2.1. Standard
The low incidence and high number of different paedi-
atric tumour types, combined with an increasing body of
new molecular information, requires basic education
and refresher courses at regular intervals. Basic educa-
tion can be obtained during paediatric oncology courses,
some of them even dedicated to radiation oncology, or
by spending a time period in a reference centre for
paediatric (radiation) oncology. International organisa-
tions such as PROS, SIOPE, ESTRO, American Society
for Radiation Oncology (ASTRO) and national societies
such as the UK Children’s Cancer and Leukemia Group
offer educational courses to refresh the knowledge on
paediatric (radiation) oncology. Moreover, a significant
number of patients in daily practice will not fit the
existing guidelines. In such situations, radiation oncol-
ogists treating paediatric patients should rely on an
(inter)national network of experts. Consequently,
attending teaching courses and meetings is recom-
mended at least once every two years. In addition,
SIOPE is working on an online textbook that will define
the ‘gold standard’ per tumour type and summarise
ongoing studies per disease site and reference radiation
oncology specialists across Europe. All radiation on-
cologists involved in paediatric oncology will be
encouraged to register for this online tool. Furthermore,
SIOPE is planning to organise (bi)monthly courses on
specific topics in paediatric oncology with room for
discussion on individual cases (Table 3).
2.2.2. Optional
In many countries, discussions are ongoing to propose a
minimal level of expertise, or number of cases treated
Table 3
Education and training.
Goals Personnel Equipment
Standard or mandatory Standard or mandatory
To get knowledge on the
‘gold standard’ in
paediatric RT
Need for basic education in paediatric radiation
oncology by
SIOPE/ESTRO (online) textbook with ‘gold standard’
policy per disease across EU
To ask for expert opinions
on difficult cases
Paediatric oncology courses dedicated to radiation
oncologists such as
Access by registration (free membership)
To get access to a (inter)
national network
ESTRO or ePROS course Chapters edited by RT chairs from SIOPE working
groups
To obtain a certification in
paediatric oncology
ESTROeASTRO congress Expiration date: 2 y
SIOPE annual meetings Web-conference system for online courses by experts on
difficult cases
National courses on paediatric RT
(certification)
Molecular biology for the paediatric radiation
oncologist (certification)
Training at a reference centre for paediatric
(radiation) oncology
Refresher courses
Mandatory (with certificate)
Optional Optional
Defining a minimum level of expertise Defining a minimum number of cases treated per
institution
ASTRO, American Society for Radiation Oncology; ESTRO, European SocieTy for Radiotherapy and Oncology; PROS, Paediatric Radiation
Oncology Society; RT, radiotherapy; SIOPE, European Society for Paediatric Oncology.
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mours faced in paediatric oncology.
2.3. Patient-related research
2.3.1. Standard
Centres are encouraged to participate and include pa-
tients in ongoing and therapy-optimising study pro-
tocols and (interdisciplinary) registries and/or adhere to
(inter)national guidelines. Registries should focus on
locoregional failure, survival, dose prescription, dose to
organs at risk and late toxicity items. Indeed, central
registration of outcomes and toxicities is of utmost
importance to demonstrate progress in the reduction of
inequalities across SIOPE-affiliated countries, which is
the main purpose of this project (Table 4).
2.3.2. Optional
Data managers can support physicians with the
administrative burden.
3. Discussion
Across countries affiliated with SIOPE, significant dis-
parities in survival and the severity of long-term side-
effects are observed [2e7]. Although the reasons for
these disparities may be multifactorial, differences in the
organisation of complex multidisciplinary care and ed-
ucation on rare diseases, such as paediatric cancers, are
probably among the most important explanations. Totackle the issue of disparities related to RT, in this
article, representatives of SIOPE, PROS, ESTRO and
CCI-Europe defined a list with ‘standard’ and ‘optional’
levels to deliver GCP-compliant treatment in paediatric
radiation oncology focussing on patient care, education
and training, as well as the organisation of patient-
related research.
Roughly one in three children diagnosed with
cancer will undergo RT with curative intent during
their disease course [12]. As the vast majority of
paediatric cancer clinics in Europe diagnose less than
one hundred new patients annually, an associated ra-
diation oncologist will treat on average of 1 or maybe
2 or 3 similar cases per year. With the growing
availability of new modalities and techniques and the
evolution in molecular biology, RT for children is
becoming increasingly complex and requires an indi-
vidualised approach. These added challenges for pae-
diatric radiation oncologists have the potential to
enhance disparities in survival and side-effects between
countries but also among centres in the same country.
Consequently, national discussions on requirements
for a minimum number of cases or patients per
treating institution (ranging from 5 to up to 50 chil-
dren treated with RT per year) are ongoing. Although
consensus on a minimum number of patients is far
from reached, it may be obvious that centres treating
a higher number of patients will benefit from their
aggregated experiences. High-volume centres may have
the opportunity to generate better techniques for
Table 4
Research.
Goals Personnel Equipment
Standard or mandatory Standard or mandatory
Participation in open study protocols of all kinds Radiation oncologists with access
to study protocols
Data registration platform
(also off-protocol)
Participation in surveys Ethical committee
Registration of outcome (including late toxicity)
Optional Optional
Data managers
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team that can participate in specialist meetings and
educational activities [13e15].
For a better understanding of resources in paediatric
RT, SIOPE mapped more than 250 paediatric RT cen-
tres across SIOPE-affiliated countries. Currently, JARC
WP9 representatives are working on an online survey
for paediatric radiation oncologists in each centre,
focussing on the standard and optional levels of orga-
nisation of patient care, education and clinical research.
The outcome of this survey will give an insight into the
strengths and weaknesses of paediatric RT across
SIOPE-affiliated countries and can be relevant for Eu-
ropean Reference Networks in terms of collaboration
pathways and referrals in paediatric RT.
4. Conclusions
With the increasing degree of complexity of RT for
paediatric cancers, establishing appropriate structures is
crucial to reduce disparities in survival rates and in the
severity of long-term side-effects. This European initia-
tive would like to encourage treating institutions to
create the appropriate environment for children
receiving radiation therapy by defining fundamental
structures and processes related to patient care, educa-
tion and training, and the organisation of patient-
related research.
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